Encision Inc., a specialized medical instruments company focused on active electrode monitoring (AEM) for laparoscopic procedures, reported QQ1 2026 results with revenue of $1.603 million, up 5.1% year-over-year and 1.1% quarter-over-quarter. Gross profit was $0.878 million, yielding a gross margin of 54.8%, signaling continued product mix strength in a low-to-mid single-digit revenue environment. However, operating expenses of $0.898 million and interest/depreciation costs produced an operating loss of $19.8 thousand and a net loss of $41.1 thousand for the quarter, with negative EBITDA of $347 thousand. The company’s per-share loss was $0.0035 (diluted), reflecting scale-related fixed costs and ongoing investments in R&D and administration as Encision positions its AEM portfolio and EndoShield protection systems for longer-term adoption. YoY revenue growth of ~5% sits against a backdrop of disciplined gross margin maintenance but near-term profitability remains constrained by the company’s investment phase and limited scale. Management commentary is not provided in the supplied transcript data, so the narrative remains anchored to the reported metrics and historical trends. Key questions for investors include the pace of adoption for AEM products, margin expansion opportunities through operating leverage, and the degree of visibility into longer-term revenue growth from new product introductions and market expansion.